Volume 19 Issue 3
Considerations for the Off-Label Use of Medications in Oncology
19 ALB. L.J. SCI. & TECH. 557 (2009)
Sarah L. Scarpace
Industry and Physicians, the Good, the Bad and the Ugly
19 ALB. L.J. SCI. & TECH. 567 (2009)
Dan R. Thompson
Off-Label Drug Use: Pros and Cons
19 ALB. L.J. SCI. & TECH. 577 (2009)
Brian Kane
Legal and Regulatory Commercial Battles
19 ALB. L.J. SCI. & TECH. 587 (2009)
Patrick Igoe
Off-Label Use From Injured Consumers' Perspective
19 ALB. L.J. SCI. & TECH. 593 (2009)
Eric Chaffin
Promotion of Off-Label Use: In Favor of a Regulatory Retreat
19 ALB. L.J. SCI. & TECH. 609 (2009)
Byron Stier
Litigation Aspects of Off-Label Use: Quality of Care, Generally Accepted Medical Practices & Emergence of Cost Containment
19 ALB. L.J. SCI. & TECH. 619 (2009)
Raul A. Tabora, Jr.
FDA's Oversight of the Promotion of Drugs for Off-Label Uses
19 ALB. L.J. SCI. & TECH. 627 (2009)
Mollie Hertel
Balancing on the Edge: The Implications and Acceptability of Off-Label Drug Use
19 ALB. L.J. SCI. & TECH. 633 (2009)
Danielle Holley